Clinical Trial: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naive, High-Risk CLL/SLL Patients

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671378) titled 'A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naive, High-Risk CLL/SLL Patients' on June 09.

Brief Summary: This study is a prospective, multicenter, open-label, single-arm phase II clinical trial evaluating the efficacy and safety of an MRD-guided, time-limited therapy with zanubrutinib combined with sonrotoclax in previously untreated high-risk CLL/SLL patients.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: CLL (Chronic Lymphocytic Leukemia)

Intervention: DRUG: Zanubrutinib and sonrotoclax

Zanubrutinib: 160 mg BID, orally, administered until Cycle 15, 21, or 27, and thereafter until disc...